<DOC>
	<DOCNO>NCT01048645</DOCNO>
	<brief_summary>Purpose : This randomized phase II trial evaluate whether combination cisplatin paclitaxel plus All-trans retinoic acid ( ATRA ) increase Response rate ( RR ) Progression-free survival ( PFS ) patient advance Non-small cell lung cancer ( NSCLC ) acceptable toxicity profile association expression Retinoic acid receptor beta 2 ( RAR-beta2 ) response biomarker . Patients Methods : Patients stage IIIB IV NSCLC include receive Paclitaxel Cisplatin ( PC ) . Patients randomize receive ATRA 20 mg/m2/day ( RA/PC ) placebo ( P/PC ) 1 week prior treatment complete two cycle . RAR-beta2 expression analyze Immunohistochemistry ( IHC ) RT-PCR tumor adjacent lung tissue .</brief_summary>
	<brief_title>Effect All-trans Retinoic Acid With Chemotherapy Based Paclitaxel Cisplatin First Line Treatment Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Purpose : This randomized phase II trial evaluate whether combination cisplatin paclitaxel plus All-trans retinoic acid ( ATRA ) increase Response rate ( RR ) Progression-free survival ( PFS ) patient advance Non-small cell lung cancer ( NSCLC ) acceptable toxicity profile association expression Retinoic acid receptor beta 2 ( RAR-beta2 ) response biomarker . Patients Methods : Patients stage IIIB IV NSCLC include receive Paclitaxel Cisplatin ( PC ) . Patients randomize receive ATRA 20 mg/m2/day ( RA/PC ) placebo ( P/PC ) 1 week prior treatment complete two cycle . RAR-beta2 expression analyze Immunohistochemistry ( IHC ) RT-PCR tumor adjacent lung tissue .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Stage III B IV NSCLC Eastern Cooperative Oncology Group ( ECOG ) performance status 02 No prior cytotoxic chemotherapy NSCLC Age â‰¥18 year , adequate laboratory measurement Measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) Life expectancy &gt; 12 week . Patients receive prior chemotherapy Patients comorbid condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>All-trans retinoic acid</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>retinoic acid receptor beta</keyword>
	<keyword>chemotherapy</keyword>
</DOC>